Adaptimmune Therapeutics (NASDAQ:ADAP - Free Report) had its price objective trimmed by Guggenheim from $3.00 to $1.75 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a buy rating on the biotechnology company's stock.
ADAP has been the subject of a number of other research reports. StockNews.com assumed coverage on shares of Adaptimmune Therapeutics in a research report on Friday, March 21st. They set a "buy" rating for the company. Mizuho decreased their price target on Adaptimmune Therapeutics from $3.00 to $1.50 and set an "outperform" rating on the stock in a research report on Wednesday, November 27th. Scotiabank cut their price objective on Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating for the company in a research report on Friday, March 21st. Finally, Wells Fargo & Company decreased their target price on Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating on the stock in a report on Friday, March 21st. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, Adaptimmune Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $1.93.
Check Out Our Latest Analysis on Adaptimmune Therapeutics
Adaptimmune Therapeutics Price Performance
Shares of ADAP stock traded down $0.01 during mid-day trading on Wednesday, reaching $0.21. The company's stock had a trading volume of 2,963,365 shares, compared to its average volume of 1,720,228. Adaptimmune Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.55. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. The company has a market cap of $52.71 million, a P/E ratio of -0.94 and a beta of 2.52. The firm's 50-day moving average is $0.51 and its two-hundred day moving average is $0.67.
Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last issued its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09). The company had revenue of $3.22 million during the quarter, compared to analyst estimates of $16.56 million. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. On average, research analysts predict that Adaptimmune Therapeutics will post -0.14 earnings per share for the current year.
Institutional Trading of Adaptimmune Therapeutics
Large investors have recently made changes to their positions in the company. Invesco Ltd. raised its holdings in shares of Adaptimmune Therapeutics by 82.0% during the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 28,526 shares during the period. Two Sigma Advisers LP raised its stake in shares of Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 58,787 shares during the period. Two Sigma Investments LP lifted its holdings in shares of Adaptimmune Therapeutics by 33.5% in the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 19,146 shares in the last quarter. Virtu Financial LLC boosted its position in shares of Adaptimmune Therapeutics by 21.5% during the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock worth $66,000 after buying an additional 21,688 shares during the period. Finally, LPL Financial LLC grew its holdings in shares of Adaptimmune Therapeutics by 106.5% during the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company's stock worth $99,000 after buying an additional 94,623 shares in the last quarter. Institutional investors own 31.37% of the company's stock.
Adaptimmune Therapeutics Company Profile
(
Get Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
See Also
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
